October 29, 2002
TAP SUBMITS NDA FOR ERECTILE DYSFUNCTION TREATMENT, UPRIMA (APOMORPHINE HCL TABLETS) SUBLINGUAL

August 5, 2002
TAP PHARMACEUTICAL PRODUCTS RECEIVES FDA APPROVAL FOR PEDIATRIC LABELING OF PREVACID® (LANSOPRAZOLE)

June 13, 2002
TAP PHARMACEUTICAL PRODUCTS AMONG FIRST TO ADOPT PHRMA MARKETING CODE OF ETHICS

May 27, 2002
RESEARCH SHOWS THAT AFRICAN AMERICAN MEN HAVE HIGHER DISEASE RECURRENCE AND LOWER QUALITY OF LIFE AFTER TREATMENT FOR PROSTATE CANCER.

May 17, 2002
PREVACID® (LANSOPRAZOLE) IS HIGHLY EFFECTIVE IN MAINTENANCE OF HEALED EROSIVE ESOPHAGITIS

April 4, 2002
PREVACID® (LANSOPRAZOLE) BECOMES #1 PRESCRIBED PROTON PUMP INHIBITOR IN THE U.S.

February 28, 2002
TAP PHARMACEUTICAL PRODUCTS ANNOUNCES THE RESULTS OF THE FIRST PUBLISHED U.S. STUDY COMPARING ESOMEPRAZOLE TO LANSOPRAZOLE

February 19, 2002
SUPPLEMENTAL NEW DRUG APPLICATION SUBMITTED TO FDA FOR USE OF PREVACID® IN PEDIATRIC PATIENTS

January 14, 2002
FIRST ORAL SUSPENSION FORMULATION FOR A PROTON PUMP INHIBITOR NOW AVAILABLE BY PRESCRIPTION